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The androgen receptor (AR) is a ligand-activated transcription factor that interacts with coregulatory
proteins during androgen-dependent gene regulation. Melanoma antigen gene protein 11 (MAGE-11) is an AR
coregulator that specifically binds the AR NH2-terminal FXXLF motif and modulates the AR NH2- and
carboxyl-terminal N/C interaction to increase AR transcriptional activity. Here we demonstrate that epidermal
growth factor (EGF) signaling increases androgen-dependent AR transcriptional activity through the post-
translational modification of MAGE-11. EGF in the presence of dihydrotestosterone stabilizes the AR-MAGE
complex through the site-specific phosphorylation of MAGE-11 at Thr-360 and ubiquitinylation at Lys-240 and
Lys-245. The time-dependent EGF-induced increase in AR transcriptional activity by MAGE-11 is mediated
through AR activation functions 1 and 2 in association with the increased turnover of AR and MAGE-11. The
results reveal a dynamic mechanism whereby growth factor signaling increases AR transcriptional activity
through the covalent modification of an AR-specific coregulatory protein. Sequence conservation of the
MAGE-11 phosphorylation and ubiquitinylation sites throughout the MAGE gene family suggests common
regulatory mechanisms for this group of cancer-testis antigens.
The androgen receptor (AR) is a ligand-dependent tran-
scription factor that mediates the effects of the biologically
active androgens testosterone and dihydrotestosterone (DHT)
on gene regulation required for male sex development and
function. Androgen-dependent gene regulation involves inter-
actions between AR and androgen response element DNA and
coregulatory proteins that link to the transcriptional machinery
of chromatin. Like other steroid receptors, AR has a multido-
main structure that includes the NH2-terminal activation do-
main 1 (AF1), which has evolved during mammalian evolution
(9, 11) and is considered predominant in AR function. Acti-
vation function 2 (AF2) in the ligand binding domain functions
as a binding site for SRC/p160 coactivator LXXLL motifs and
for the FXXLF motif in the AR NH2 terminus and in several
putative AR coregulatory proteins (23, 25, 27). Cell-free fluo-
rescence binding studies have shown that the AR20-30 FXXLF
motif peptide binds to AF2 with 5- to 10-fold-higher affinity
than an LXXLL motif containing a peptide from the most
active ARSRC/p160 coactivator (23) and is the basis of the
androgen-dependent AR NH2-terminal and carboxyl-terminal
(N/C) interaction important for androgen-induced gene acti-
vation (7, 25, 26, 30, 40). The AR N/C interaction slows the
dissociation rate of bound androgen (62), stabilizes AR bind-
ing to androgen response element DNA (60), and appears to
be involved in domain swapping between an intramolecular
AR monomer in the cytoplasm and an intermolecular antipa-
rallel AR dimer in the nucleus (39, 51). The importance of the
N/C interaction for AR function is supported by studies on the
human androgen insensitivity syndrome, in which naturally
occurring single amino acid mutations in AF2 reduce binding
of the AR FXXLF and SRC/p160 LXXLL motifs without
altering the apparent equilibrium androgen binding affinity
(15, 22, 34, 49). The different physiological potencies of tes-
tosterone and DHT have been linked to ligand-specific effects
transmitted to the AF2 surface, where the weaker potency of
testosterone, a more polarized steroid than DHT, derives from
its inability to fully stabilize the AF2 binding surface for AR
FXXLF and SRC/p160 coactivator LXXLL motif binding (1).
Recently, we demonstrated that the androgen-dependent
AR N/C interaction is modulated by the AR coregulatory
protein, melanoma antigen gene protein 11 (MAGE-11) of the
MAGE-A gene family (3). MAGE-11 was identified in a two-
hybrid screen of a human testis library using the AR FXXLF
motif and flanking sequence as bait. MAGE-11 binds the AR
NH2-terminal FXXLF motif region, competes for the AR N/C
interaction, and increases AR transcriptional activity in part by
exposing AF2 for SRC/p160 coactivator recruitment. MAGE-11
binding to the AR FXXLF motif is selective. MAGE-11 does not
interact with the FXXLF motif regions present in the putative
AR coregulators ARA-70, ARA-54, and ARA-55, even though
these same FXXLF motifs mediate coactivator interaction with
the AR AF2 site (3, 27). Based on coimmunoprecipitation ex-
periments, AR and MAGE-11 form a stable complex in the
absence of androgen, but their association is transient in the
presence of androgen (3). These results brought into question
the mechanisms whereby MAGE-11 modulates androgen-in-
duced gene regulation by AR. We have also shown that epi-
dermal growth factor (EGF) can increase AR transcriptional
activity through mechanisms that involve coactivators (16), and
EGF receptor signaling has been linked to increased AR tran-
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scriptional activity in prostate cancer (12, 43). There is also
evidence in prostate cancer cells for ligand-independent acti-
vation of AR through second messengers (13).
In this report we sought to identify the underlying mecha-
nisms that account for the transient nature of the MAGE-AR-
DHT complex. Our studies demonstrate that EGF promotes
the formation of a more stable MAGE-AR-DHT complex
through site-specific ubiquitinylation at two lysine residues re-
quired for MAGE-11 to interact with the AR FXXLF motif.
EGF-induced ubiquitinylation of MAGE-11 is linked to phos-
phorylation of MAGE-11, more rapid turnover of AR and
MAGE-11, and increased AR transcriptional activity.
MATERIALS AND METHODS
Plasmids. pCMVhAR (pCMV-AR), coding for full-length human AR amino
acid residues 1 to 919 (45), pCMV-AR1-660 (53), VP-AR1-660 (25), GAL-
AR16-36 (28), pSG5-MAGE-1-429, coding for full-length MAGE-11 (pSG5-
MAGE), Flag-MAGE-2-429 (Flag-MAGE), GAL-MAGE-2-429 (GAL-MAGE),
VP-MAGE-2-429 (VP-MAGE) (3), and pSG5-TIF2 (59) were previously described.
Flag-ubiquitin (Flag-Ub), coding for a single ubiquitin protein, was kindly pro-
vided by Stephanie L. H. Miller and John P. O’Bryan. pSG5-6His-HA-Ub-KO,
coding for lysine-free ubiquitin and in which all lysine residues are converted to
arginine, was kindly provided by David Lonard and Bert O’Malley. Flag-Ub-KO,
coding for lysine-free ubiquitin with all lysines mutated to arginine, was created
by subcloning Ub-2-76-KO into the HindIII/BamHI sites of pCMV-Flagb. Mu-
tagenic primers were used in single and double PCRs to prepare the AR and
MAGE-11 mutants. pCMV-AR120–472 was created by double PCR mutagen-
esis of pCMV-AR with the BglII/KpnI fragment inserted at the same sites of
pCMV-AR.
pSG5-MAGE221–249 and pSG5-MAGE with single mutations K225A,
K236A, and K245A, double mutation K240A,K245A, and triple mutation
K236A,K240A,K245A were created by double PCR mutagenesis using pSG5-
MAGE as template and inserting the EcoRI/BglII-digested fragments into the
same sites in pSG5-MAGE. pSG5-MAGE-K225A,K236A,K240A,K245A was
created by double PCR mutagenesis of pSG5-MAGE-K236A,K240A,K245A and
the EcoRI/BglII-digested fragment inserted into the same sites in pSG5-MAGE-
K236A,K240A,K245A. pSG5-MAGE serine- and threonine-to-alanine mutants
were created using pSG5-MAGE as template by double PCR site-specific mu-
tagenesis or by QuikChange site-directed mutagenesis (Stratagene). PCR-am-
plified fragments were digested with EcoRI/XhoI (S174A and S168A,S170A,
S174A) or EcoRI/BglII and inserted into the same sites of pSG5-MAGE.
pSG5-HA-MAGE-112-429, pSG5-HA-MAGE-2-429221–249 (HA-MAGE
221–249), and pSG5-HA-MAGE-112-429 with mutations K236A, K240A,
T360A, and K236A,K240A,K245A were created by PCR amplifying the corre-
sponding wild-type or mutant pSG5-MAGE and inserting the EcoRI/XhoI-
digested fragments into the same sites of pSG5-HA that code for a fusion protein
linked to the NH2-terminal human influenza virus hemagglutinin (HA) tag.
pSG5-HA-MAGE-2-252, wild-type and mutant pSG5-HA-MAGE-112-362, and
pSG5-HA-MAGE-2-362 were created by PCR mutagenesis of the corresponding
pSG5-MAGE mutants and inserting the EcoRI/SalI-digested fragment into the
EcoRI/XhoI sites of pSG5-HA. pSG5-HA-MAGE-112-362-T360A was created
by QuikChange site-directed mutagenesis. pSG5-HA-MAGE-112-429-S168A,
S170A,S174A,S181A,S199A,S208A (6-SA) was created by sequentially introduc-
ing the S208A, S181A, and S199A mutations into pSG5-HA-MAGE-112-429-
S168A,S170A,S174A by cloning the PCR-amplified fragments into the EcoRI/
XhoI sites.
Flag-MAGE221–249 and Flag-MAGE with K240A, K225A,K236A,K240A,
K245A, and T360A mutations were created by PCR amplifying the corresponding
mutants in pSG5-MAGE and inserting the EcoRI/XhoI-digested fragments into
the EcoRI/SalI sites of pCMV5-Flagb. VP-MAGE221–249 and GAL-
MAGE221–249 were created by PCR amplifying pSG5-MAGE221–249 and
inserting the EcoRI/XhoI-digested fragments into the EcoRI/SalI sites of pVP16
and GAL-0. All PCR-amplified regions were verified by DNA sequencing.
DNA transfection in cultured cells. Monkey kidney CV1 cells were maintained
and transfected using calcium phosphate DNA precipitation as described else-
where (21, 22). CV1 cells (4.2  105 cells/6-cm dish) were transfected with 0.1 g
pCMV-AR or 0.1 g pCMV-AR120–472 in the absence and presence of 2 g
pSG5-TIF2, 1 or 2 g wild-type or mutant pSG5-MAGE, and 5 g prostate-
specific antigen enhancer luciferase (PSA-Enh-Luc) or 5 g mouse mammary
tumor virus luciferase (MMTV-Luc) reporter vectors. After transfection, CV1
cells were placed in serum-free, phenol red-free medium in the absence and
presence of 1 nM DHT. Twenty-four h later, the media with and without DHT
were exchanged, and the next day luciferase activity was measured.
The effects of wild-type and mutant MAGE-11 on AR AF1 constitutive activity
were determined in HeLa cells maintained and transfected using FuGENE-6
transfection reagent (Roche Applied Science) as described previously (1). HeLa
cells (5  104 cells/well in 12-well plates) were transfected with 0.1 g PSA-Enh-
Luc and 0.01 g pCMV-AR1-660 in the absence and presence of 0.1 g wild-type
or mutant pSG5-MAGE. The following day the medium was changed to serum-
free, phenol red-free medium, and cells were incubated for another 24 h before
measuring luciferase activity.
Two hybrid interaction assays were performed in HeLa cells using FuGENE-6
as described elsewhere (1). HeLa cells (5  104 cells/well in 12-well plates) were
transfected with 0.1 g 5XGAL4Luc3 luciferase reporter vector, 0.05 g wild-
type or mutant GAL-MAGE or VP-MAGE, and 0.05 g pVP16, VP-AR1-660,
or GAL-AR16-36. The next day the medium was changed to serum-free, phenol
red-free medium, and luciferase activity was measured after 24 h.
Human endometrial Ishikawa cells were maintained in Eagle’s minimum es-
sential medium supplemented with 10% fetal bovine serum, penicillin, strepto-
mycin, and 2 mM L-glutamine. Ishikawa cells (105 cells/well in 12-well plates)
were transfected using FuGENE-6 with 0.1 g PSA-Enh-Luc or 0.1 g MMTV-
Luc with 0.01 g pCMV-AR or pCMV-AR1-660 in the absence and presence of
0.1 g wild-type and mutant pSG5-MAGE (2). After 24 h, cells were treated in
serum-free, phenol red-free medium for 24 h in the absence and presence of
EGF. For small interfering RNA (siRNA) experiments, Ishikawa cells (7.5  104
cells/well in 12-well plates) were transfected in antibiotic-free medium using
Lipofectamine 2000 reagent (Invitrogen) with 0.1 g MMTV-Luc and 0.025 g
pCMV-AR in the absence and presence of 2 nM MAGE-11 siRNA with the
following sense sequences: siRNA-1, GGAGGGAUCCCACUUCUUAUU;
siRNA-2, GCACUGAUCCUGCAUGCUAUU; siRNA-3, CAACUGCUCUU
UGGCAUUGUU (Dharmacon RNA Technologies). The next day cells were
placed in serum-free, phenol red-free medium without hormone treatment. After
24 h the medium was replaced with and without 0.1 nM DHT and 10 ng/ml EGF,
cells were cultured for another 24 h, and luciferase activity was measured.
For transfections in CV1, HeLa, and Ishikawa cells, luciferase activity was
determined using a Lumistar Galaxy automated multiwell plate reader luminom-
eter (BMG Labtech). All of the luciferase data are representative of at least
three independent experiments.
Immunochemical procedures. Immunoprecipitation and immunoblotting ex-
periments were performed using monkey kidney COS-1 cells maintained in
Dulbecco’s modified Eagle’s medium and transfected in 10-cm dishes using
DEAE dextran as described previously (21). For each coimmunoprecipitation,
two 10-cm dishes containing 1.8  106 to 2.5  106 COS cells were transfected
with the indicated amounts of Flagb empty vector, wild-type and mutant Flag-
MAGE, Flag-Ub and Flag-Ub-KO with and without pCMV-AR, and wild-type
and mutant pSG5-HA-MAGE and pooled. For phosphothreonine analysis, COS
cells were transfected with wild-type pSG5-HA-MAGE-112-429 and the T360A
mutant. Twenty-four h after transfection, cells were placed in serum-free, phenol
red-free medium for the indicated times in the absence and presence of DHT
and EGF and harvested in 1 ml phosphate-buffered saline (PBS)/10-cm dish.
Cells were pelleted by centrifugation and solubilized in 1 ml immunoprecipita-
tion (IP) lysis buffer containing 0.15 M NaCl, 0.5% NP-40, 50 mM NaF, 50 mM
Tris-HCl, pH 7.5, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and
protease inhibitor cocktail (Roche). Protein extracts were precleared with 100 l
agarose (Sigma), and extracts were incubated with 15 l anti-Flag M2 affinity gel
(Sigma) for 1 to 2 h or overnight at 4°C and washed four times with IP lysis
buffer. For phosphothreonine analysis, extraction buffer contained, in addition,
phosphatase inhibitor cocktail 1 and 2 (Sigma), and equivalent amounts of
protein extract were immunoprecipitated using anti-HA affinity matrix (rat poly-
clonal; 15 l resin/470 g protein; Roche). Adsorbed proteins were released in
50 l 2 sample buffer (3.3% sodium dodecyl sulfate [SDS], 10% glycerol, 10%
2-mercaptoethanol, and 0.12 M Tris-HCl, pH 6.8) and analyzed by immunoblot-
ting as described elsewhere (3) in 10% acrylamide gels containing SDS. Blots
were exposed to antibodies as described below and developed for chemilumi-
nescence (SuperSignal Western; Pierce Biotechnology, Inc., Rockford, IL).
Immunoblot assays were performed by transient expression in COS cells in
10-cm dishes using DEAE dextran as described above. Cells were solubilized in
immunoblot (IB) lysis buffer containing 0.15 M NaCl, 1% Triton X-100, 0.1%
SDS, 1% sodium deoxycholate, 0.5 mM EDTA, 50 mM Tris-HCl, pH 7.5, 1 mM
phenylmethylsulfonyl fluoride, and protease inhibitor cocktail (Roche). For
GAL-4 or VP16 fusion proteins, cells were transferred to serum-free, phenol
red-free medium containing 1 M MG132, a proteosome inhibitor, 24 h after
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transfection, fresh medium containing 1 M MG132 was added the next day, and
cells were harvested 1 h later. For siRNA experiments, COS cells (4  105/well
in six-well plates) were transfected using Lipofectamine 2000 in DMEM without
antibiotics with 0.5 g pSG5-MAGE with and without 10 nM MAGE-11 siRNA,
and cells were incubated for 48 h in serum-free, phenol red-free medium, har-
vested in PBS, and extracted in IB lysis buffer. Protein extracts were combined
with 0.2 volumes of 6 sample buffer (10% SDS, 30% glycerol, 30% 2-mercap-
toethanol, and 0.35 M Tris-HCl, pH 6.8), separated on 10 or 12% acrylamide gels
containing SDS, and electrophoretically transferred to nitrocellulose mem-
branes. Blots were probed as indicated using AR32 antipeptide antibody (rabbit
polyclonal, 0.4 g/ml) (48, 55), anti-Flag M2 monoclonal antibody (mouse mono-
clonal, 1:2,000 dilution; Sigma), HA-tag antibody (ab9110; rabbit polyclonal,
1:2,000 dilution; Abcam), rabbit anti-peptide MAGE-11 antibodies MagAb13-26
(3 or 4 g/ml) and MagAb59-79 (3 or 4 g/ml) (2), GAL-4 DNA binding domain
antibody (sc-577; rabbit polyclonal, 1:500 dilution; Santa Cruz Biotechnology),
VP16 activation domain antibody (sc-7546; mouse monoclonal, 1:100 dilution;
Santa Cruz Biotechnology), phosphothreonine antibody (rabbit polyclonal,
1:1,000 dilution; Cell Signaling), and -actin antibody (1:5,000 dilution; Abcam).
MAGE-11 antibodies MagAb13-26 and MagAb59-79 were raised against
MAGE-11 NH2-terminal peptides and purified by peptide affinity chromatogra-
phy (2). Data reported for all immunoprecipitation and immunoblot experiments
are representative of two or more independent experiments.
Protein degradation rates. [35S]methionine pulse-chase experiments were per-
formed in COS cells in 10-cm dishes transfected using DEAE dextran as de-
scribed elsewhere (21). Twenty-four h after transfection, cell cultures were
placed in serum-free medium in the absence and presence of 10 ng/ml EGF. The
next day, cells were washed in PBS and incubated in 4 ml methionine-free
Dulbecco’s modified Eagle’s medium (Life Technologies, Inc.) containing 20
mM HEPES, pH 7.2 in the absence and presence of 10 ng/ml EGF. After 20 min
at 37°C, 80 Ci [35S]methionine (1,175 Ci/mmol; Easy Tag Express labeling mix;
Perkin-Elmer) was added to each 10-cm dish, and cells were incubated for 30 min
at 37°C. Cells were washed with PBS, and serum-free, phenol red-free, methi-
onine-containing medium was added with and without 10 ng/ml EGF. At each
time point, the medium was replaced on all plates and cells were harvested in 1
ml PBS after washing twice with PBS and sedimenting by centrifugation. Proteins
were extracted in IB lysis buffer containing 1 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl fluoride, and proteinase inhibitor cocktail (Sigma). Cells were
sheared using a 1-ml pipetteman, incubated for 15 min at 4°C, and sedimented
by centrifugation. The supernatant was combined with 8 g MagAb13-26 and 10
l protein A beads (Sigma). After 2 h of incubation at 4°C, beads were sedi-
mented by centrifugation and washed twice in IB lysis buffer. Protein was solu-
bilized in 50 l 2 SDS sample buffer and analyzed on 10% acrylamide gels
containing SDS. Proteins were transferred electrophoretically to nitrocellulose
membranes and exposed to X-ray film. Autoradiographs were scanned and
analyzed for optical density using an Image-Pro Plus spectrophotometer (Media
Cybernetics, Silver Spring, MD).
Mass spectrometry. COS cells in 120 10-cm dishes (2  106 cells/dish) were
transfected with 5 g pSG5-MAGE/dish using DEAE dextran (21). Twenty-four
h after transfection, cells were transferred to serum-free, phenol red-free me-
dium containing 10 ng/ml EGF. The next day the medium was replaced and cells
were harvested 2.5 h later in IP lysis buffer. MAGE-11 antibody MagAb13-26
purified on a peptide affinity column (3) was eluted in 25 mM sodium citrate-
HCl, pH 2.5, and neutralized with 0.1 M sodium phosphate, pH 8.0. MAGE-11
protein was purified using 500 g peptide purified MagAb13-26 antibody (3)
coupled to 100 l CNBr-activated Sepharose 4B (Amersham) according to the
manufacturer’s instructions and eluted in 10% ethanol and 10% formic acid for
proteomic analysis by the Specialized Cooperative Centers Program in Repro-
duction and Infertility Research Proteomics Core of the UNC Chapel Hill—
Duke Proteomics Center, Program in Molecular Biology and Bioinformatics.
In vitro kinase assay. Glutathione S-transferase (GST) fusion peptides GST-
MAGE-354EPKRLLTQN362, GST-MAGE-354EPKRLLAQN362 T360A mutant,
and truncated human Cdc25C isoform A GST-210GLYRSPSMPE219 Chk1 ki-
nase substrate were expressed by cloning annealed oligos coding for the peptides
into the EcoR1/Xho1 sites of pGEX-4T-1. For rapid insert verification, the 5
oligo contained a 5-AATTT end that disrupts the EcoR1 site after ligation.
Fusion peptides were expressed in BL21-DE3 E. coli by inducing with 1 mM
isopropyl-1-thio--D-galactopyranoside at 15°C overnight. Proteins were ex-
tracted from the pellet of a 100-ml culture using 4 ml GST extraction buffer (0.1
M NaCl, 1 mM EDTA, 0.5% NP-40, 20 mM Tris-HCl, pH 8.0, 1 mM phenyl-
methylsulfonyl fluoride, and proteinase inhibitor cocktail) by sonication and
centrifugation. The bacterial lysate (0.5 ml) was combined with 10 l GST-
Sepharose 4B beads (Amersham Biosciences) and incubated for 2 h at 4°C.
Beads were washed and suspended in 1.5 ml GST extraction buffer. Aliquots
separated by gel electrophoresis were stained using GelCode Blue stain reagent
(Pierce) to verify equivalent expression. Each of the GST-peptide–Sepharose
bead suspensions (50 l) was washed in Chk1 kinase buffer (1 mM EGTA, 0.4
mM EDTA, 5 mM MgCl2, 0.05 mM DTT, and 5 mM morpholinepropanesulfo-
nic acid, pH 7.2), pelleted with the 10 l kinase buffer remaining, and com-
bined with 10 l kinase buffer containing 1 l full-length recombinant GST-Chk1
protein expressed from Sf9 cells (82 kDa; 0.1-mg/ml stock; specific activity, 369
nmol/min/mg; BioVision), 5 l 0.25 mM cold ATP containing 0.16 Ci/l
[-32P]ATP (10 mCi/ml, 3,000 Ci/mmol; Perkin-Elmer), and incubated at 30°C
for 30 min. SDS sample buffer (6; 7 l) was added, and samples were boiled for
3 min and separated on a small 12% acrylamide gel containing SDS. The gel was
dried under vacuum at 70°C for 1 h, exposed to X-ray film for 15 h, and then
rehydrated in PBS and stained with brilliant blue R250 (Sigma) to verify equiv-
alent protein loading.
RESULTS
EGF stabilizes the MAGE-AR-DHT complex. To investigate
the transient nature of the AR and MAGE-11 complex in the
presence of DHT, we determined the effects of EGF on the
coimmunoprecipitation of AR with MAGE-11. Without EGF,
AR coimmunoprecipitated with Flag-MAGE in the absence of
DHT but was barely detected in the presence of DHT (Fig. 1A,
top panel, lanes 5 and 6), as reported previously (3). However,
FIG. 1. EGF stabilizes the MAGE-AR-DHT complex. (A) COS cells were transfected with 2 g pCMV-AR and 4 g Flagb empty vector (lanes
1 to 4) or 2 g pCMV-AR and 4 g Flag-MAGE (lanes 5 to 8). Cells were treated with and without 10 nM DHT and 100 ng/ml EGF for 24 h
as indicated. Fresh medium was added the next day and after 2.5 h. Cells were harvested, and protein extracts were prepared in IP lysis buffer for
immunoprecipitation using anti-Flag affinity resin. Transfer blots of the immunoprecipitates (upper two panels) and cell extracts (8 g protein/lane;
lower two panels) were developed using AR32 and anti-Flag antibodies. (B) COS cells were transfected with 2 g pCMV-AR and 5 g Flagb
(lanes 1 to 4) or 2 g pCMV-AR and 5 g Flag-MAGE (lanes 5 to 18) and 24 h later placed in serum-free, phenol red-free medium without
hormone. The next day the medium was replaced with and without 10 nM DHT and 10 ng/ml EGF and incubated at 37°C from 1 to 10 h
as indicated. Anti-Flag immunoprecipitates (upper two panels) and cell extracts (10 g protein/lane; lower two panels) were prepared and
assayed as for panel A.
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when cells were treated with EGF for 26 h, AR coimmuno-
precipitated with MAGE-11 to a similar extent in the absence
and presence of DHT (Fig. 1A, lanes 7 and 8). Immunopre-
cipitation of AR did not result from nonspecific aggregation,
since AR was not detected in immunoprecipitates when using
the Flag empty vector (Fig. 1A, lanes 1 to 4, and B, lanes 1 to
4). The low level of AR in cell extracts in the absence of DHT
and MAGE-11 (Fig. 1A, third panel, lane 1) was detected after
a longer film exposure (data not shown) and reflects the in-
crease in AR degradation in the absence of MAGE-11 and
without the stabilizing effect of the androgen-dependent AR
N/C interaction (21, 35).
We found that the stabilizing influence of EGF on the
MAGE-AR-DHT complex was time dependent, requiring 7 to
10 h of exposure of cells to EGF (Fig. 1B, top panel, lanes 12
to 18). In the absence of DHT, the levels of the MAGE-AR
complex paralleled the levels of AR and MAGE-11 (Fig. 1B,
lanes 5 to 11).
EGF and MAGE-11 regulate AR steady-state levels in the
absence and presence of DHT. Immunoblots of protein ex-
tracted from cells treated in the absence of EGF without the
coexpression of MAGE-11 showed higher levels of AR in the
presence of increasing concentrations of DHT (Fig. 2A, top
panel, lanes 1 to 8). This reflects the stabilizing effect of the
androgen-dependent AR N/C interaction (21, 38, 62). How-
ever, DHT-bound AR levels were lower in the presence of
EGF, suggesting EGF signaling interferes with the AR N/C
interaction. With the coexpression of MAGE-11, AR levels
increased overall but declined at 2 and 5 nM DHT in the
absence and presence of EGF, with a further EGF-dependent
decline at 10 nM DHT (Fig. 2A, lanes 11 to 18).
The decrease in AR in the presence of DHT with the
coexpression of MAGE-11 appears to reflect the inhibitory
effect of MAGE-11 on the AR N/C interaction (3), which
was accentuated by EGF. The EGF-dependent lower level
of AR at 10 nM DHT raised the possibility that EGF acting
through MAGE-11 enhances the previously reported ability
of MAGE-11 to increase AR turnover in the presence of
DHT (3).
EGF increases MAGE-11 degradation in the presence of
AR. To explore the mechanisms underlying EGF-dependent
stabilization of the MAGE-AR complex, we determined the
effects of EGF on MAGE-11 turnover in the presence of AR
by immunoblotting and by [35S]methionine pulse-chase analy-
sis. When MAGE-11 was coexpressed with AR for 26 h in the
presence of increasing concentrations of DHT, steady-state
levels of MAGE-11 declined to the greatest extent in the pres-
ence of EGF at a saturating concentration of 10 nM DHT (Fig.
2A, second panel, lanes 9 to 18). [35S]methionine pulse-label-
ing experiments performed in the absence of DHT indicated
faster degradation rates of MAGE-11 in the presence of AR
and EGF than with either AR or EGF alone (Fig. 2B). The
half-life of MAGE-11 decreased from 5 to 6 h at 37°C in the
presence of AR or EGF to 1.7 h with both AR and EGF
(Fig. 2C).
The results suggest that the increased turnover of MAGE-11
accounts for the EGF- and AR-dependent decrease in
MAGE-11 levels. Moreover, EGF-dependent stabilization of
the MAGE-AR complex in the absence and presence of DHT
(Fig. 1A) occurs in association with the increased turnover of
AR and MAGE-11.
EGF enhances the ubiquitinylation of MAGE-11. The in-
crease in MAGE-11 turnover in the presence of AR and EGF
raised the possibility that EGF modulates the MAGE-AR
complex through the ubiquitinylation of MAGE-11. This hy-
pothesis was supported by the results of immunoblot assays
performed in the absence and presence of AR and probed with
a MAGE-11-specific antibody. In addition to the major 70-
kDa MAGE-11 band detected without the coexpression of AR,
EGF caused the appearance of a weaker 80-kDa band that
was not present after EGF treatment in the absence of
MAGE-11 (Fig. 3A, lanes 1 to 4). A 130-kDa immunoreac-
FIG. 2. EGF regulates the turnover of AR and MAGE-11.
(A) COS cells were transfected with 4 g pCMV-AR (lanes 1 to 8), 4
g pSG5-MAGE (lanes 9 and 10), and 4 g pCMV-AR with 4 g
pSG5-MAGE (lanes 11 to 18). Cells were treated 24 h after transfec-
tion with and without 2, 5, and 10 nM DHT in the absence and
presence of 100 ng/ml EGF as indicated. Cells were harvested 48 h
later in IB lysis buffer and analyzed (10 g protein/lane) on a 10%
acrylamide gel containing SDS. The transfer blot was probed with
AR32, MagAb13-26, and -actin antibodies as indicated. (B) COS
cells were transfected with 2 g pSG5-MAGE without (lanes 1 to 8)
and with 2 g pCMV-AR (lanes 9 to 16). Twenty-four h after trans-
fection, cells were placed in serum-free, phenol red-free medium in the
absence (lanes 1 to 4 and 9 to 12) and presence (lanes 5 to 8 and 13 to
16) of 10 ng/ml EGF. The next day cells were placed in methionine-
free medium with or without EGF and incubated for 30 min with
[35S]methionine. The medium was replaced with serum-free, methi-
onine-containing medium with and without EGF, and cells were har-
vested at 0, 2.5, 5, and 8 h. Cell extracts containing 0.35 mg protein
were immunoprecipitated using MagAb13-26, and the transfer blot
was exposed to X-ray film. (C) Quantitation of 35S labeling. The au-
toradiograph in panel B was scanned using an Image Pro Plus spec-
trophotometer, and the data are plotted on a semilog scale.
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tive MAGE-11 band was also detected in the absence and
presence of EGF (Fig. 3A, lanes 3 and 4), and there was a
slightly faster migrating minor band, possibly resulting from
partial degradation.
With the coexpression of AR, the 80- and 130-kDa forms of
MAGE-11 were barely detected in the absence of EGF (Fig.
3A, lane 5). However, in the presence of AR and EGF, a
ladder of more intense higher-molecular-mass bands that in-
cluded the EGF-induced 80-kDa band seen in the absence of
AR was evident with the MAGE-11 antibody (Fig. 3A, lanes 4
and 6). Absence of the slower migrating protein bands when
AR was expressed by itself (Fig. 3A, lanes 7 and 8) provided
further evidence that the protein bands represent modified
forms of MAGE-11.
To determine whether the slower migrating immunoreactive
forms of MAGE-11 resulted from ubiquitinylation, we coex-
pressed Flag-tagged ubiquitin with HA-MAGE-112-429, an
HA-tagged carboxyl-terminal fragment of MAGE-11 that in-
teracts with AR (3). In the absence and presence of EGF,
ubiquitinylated forms of MAGE-11 were suggested by the
Flag-Ub immunoprecipitates and cell extracts detected using
an HA tag antibody (Fig. 3B, lanes 3 to 6). After treatment
with EGF, an additional ladder of slower migrating MAGE-11
bands coimmunoprecipitated with Flag-Ub and was present in
the cell extract (Fig. 3B, lanes 4 and 5).
The 130-kDa band evident in the cell extracts and immu-
noprecipitates (Fig. 3A and B) appeared to represent a
MAGE-11 homodimer that persisted after reducing denatur-
ation and analysis in SDS-containing gels. Immunoprecipita-
tion of the MAGE-11 dimer by the Flag antibody after coex-
pression with Flag-Ub indicated that the dimer was also likely
ubiquitinylated in response to EGF (Fig. 3B, lanes 3 and 4).
Dimerization of MAGE-11 was supported by experiments
where we coexpressed Flag-MAGE with pSG5-HA-MAGE.
FIG. 3. MAGE-11 ubiquitinylation and dimerization. (A) Effects of EGF and AR on MAGE-11 ubiquitinylation. COS cells were transfected
with 2 g pSG5 empty vector (p5, lanes 1 and 2), 2 g pSG5-MAGE in the absence (lanes 3 and 4) or presence (lanes 5 and 6) of 2 g pCMV-AR,
and 2 g pCMV-AR alone (lanes 7 and 8) and treated 24 h later with and without 10 ng/ml EGF as indicated. The next day the medium was
replaced with fresh medium with or without EGF. Cell extracts were prepared 2 h later in IB lysis buffer and analyzed (50 g/lane) on a 10%
acrylamide gel. The transfer blot was probed using MagAb59-79 antibody. (B) EGF-induced ubiquitinylation of MAGE-11. COS cells were
transfected with 6 g Flagb empty vector and 3 g pSG5-HA-MAGE-112-429 (lanes 1, 2, and 6) or 6 g FlagUb and 3 g pSG5-HA-MAGE-
112-429 (lanes 3 to 5) and treated 24 h later in the absence (lanes 1, 3, and 6) or presence (lanes 2, 4, and 5) of 100 ng/ml EGF. The next day,
protein extracts were prepared in IP lysis buffer, and anti-Flag resin was used to immunoprecipitate FlagUb. Shown are immunoprecipitated
proteins (IP; lanes 1 to 4) and cell extracts (25 g protein/lane; lanes 5 and 6). The transfer blot was probed using HA tag antibody. (C) EGF-
and AR-independent dimerization of MAGE-11. COS cells were transfected with 4 g Flag-b and 2 g pCMV-AR (lanes 1 to 4), 4 g Flagb and
2 g pSG5-HA-MAGE (lanes 5 and 6), 4 g Flag-MAGE and 2 g pSG5 (lanes 7 and 8), 4 g Flag-MAGE and 2 g pSG5-HA-MAGE (lanes
9 and 10), and 4 g Flag-MAGE, 2 g pCMV-AR, and 2 g pSG5-HA-MAGE-11 (lanes 11 to 14). Cells were treated 24 h later with and without
10 nM DHT and 100 ng/ml EGF as indicated. The next day the media were exchanged, and 2 h later cells were harvested in IP lysis buffer and
protein extracts were immunoprecipitated using anti-Flag M2 affinity gel. Immunoprecipitates (upper three panels) and cell lysates (10 g
protein/lane; lower four panels) were analyzed on 10% acrylamide gels containing SDS, and the transfer blots were probed using AR32, HA, Flag,
and -actin antibodies as indicated.
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HA-MAGE-11 coimmunoprecipitated with Flag-MAGE in
the absence and presence of AR and EGF (Fig. 3C, upper
panels, lanes 9 to 14). The DHT- and EGF-dependent coim-
munoprecipitation of AR with Flag-MAGE-11 (Fig. 3C, upper
panel, lanes 11 to 14) was similar to that seen in Fig. 1A and
did not result from an effect of EGF on MAGE-11 dimeriza-
tion.
The results suggest that EGF increases the ubiquitinylation
of MAGE-11 in association with stabilization of the AR-
MAGE complex independent of an effect on MAGE-11 dimer-
ization.
Region of ubiquitinylation in MAGE-11. To localize the
region in MAGE-11 that harbors EGF-dependent ubiquitiny-
lation sites, we expressed a series of HA-MAGE fragments,
shown schematically in Fig. 4A. Using an HA tag antibody, we
found that the carboxyl-terminal MAGE-112-429 fragment
and central fragment MAGE-112-362 exhibited EGF-depen-
dent ladders of slower migrating bands (Fig. 4B). There was
also a slower migrating band less dependent on EGF, indica-
tive of MAGE-11 dimerization. In contrast, MAGE-2-429 and
NH2-terminal fragments 2–362 and 2–252 each had an EGF-
dependent slower migrating band similar in intensity and mo-
bility shift to the 80-kDa form of MAGE-11 seen with full-
length 70-kDa MAGE-11 (Fig. 3A). The dimer band not
apparent with the NH2-terminal fragments of MAGE-11 (Fig.
4B) was detected on longer exposure of the film (data not
shown).
The presence of four potential lysine ubiquitinylation sites
FIG. 4. Region of ubiquitinylation in MAGE-11. (A) Schematic diagram of full-length MAGE-11 (amino acid residues 1 to 429) and fragments.
The amino acid sequence is shown for the MAGE-11 nuclear localization signal (NLS; residues 18 to 22) and the amino acid 221 to 249 region
that contains Lys-225, -236, -240, and -245. (B) Ubiquitinylation in the central region of MAGE-11. COS cells were transfected with 5 g pSG5-
HA-MAGE-2-429 (lanes 1 and 2), 1 g pSG5-HA-MAGE-112-429 (lanes 3 and 4), 5 g pSG5-HA-MAGE-2-252 (lanes 5 and 6), 1 g pSG5-HA-
MAGE-112-362 (lanes 7 and 8), or 5 g pSG5-HA-MAGE-2-362 (lanes 9 and 10) and 24 h later treated in the absence or presence of 10 ng/ml
EGF as indicated. The next day the media with and without EGF were replaced and again incubated for 2.5 h. After the second 2.5-h incubation,
protein extracts were prepared in IB lysis buffer containing 50 mM NaF and phosphatase inhibitor cocktail 1 and 2 (Sigma) and analyzed (15 to
25 g/lane) by immunoblotting using HA tag antibody. (C) Loss of the MAGE-11-dependent increase in AR transcriptional activity by
MAGE221-249. CV1 cells were transfected with 5 g PSA-Enh-Luc and 0.1 g pCMV-AR with and without 2 g pSG5-MAGE and 2 g pSG5-
MAGE221-249 as indicated. Cells were incubated in the absence and presence of 1 nM DHT for 48 h, and luciferase activity was determined.
(D) Reduced interaction between AR and MAGE221-249. COS cells were transfected with 2 g pCMV-AR in the presence of 4 g Flagb empty
vector (lanes 1 to 4), 4 g Flag-MAGE (lanes 5 to 8), and 4 g Flag-MAGE221-249 (lanes 9 to 12) and 24 h later cultured in the absence and
presence of 10 nM DHT and 100 ng/ml EGF as indicated. The next day the media were replaced and cells were incubated an additional 2.5 h. Cells
were extracted in IP lysis buffer and immunoprecipitated using anti-Flag affinity resin. Shown are immunoblots of immunoprecipitates (upper
panel) and cell extracts (8 g/lane; lower panel) probed with AR32 and anti-Flag antibodies. (E) Loss of AR interaction with MAGE221-249.
Luciferase activity was determined in two-hybrid assays using HeLa cells transfected with 0.1 g 5XGAL4Luc3 and 0.05 g GAL-MAGE or
GAL-MAGE221-249 with 0.05 g VP16 or VP-AR1-660 as indicated and with 0.05 g VP-MAGE or VP-MAGE221-249 with 0.05 g GAL-0
or GAL-AR16-36 as indicated. In the lower panel, immunoblots of extracts from COS cells transfected with 10 g GAL-MAGE, GAL-MAGE
221-249, VP-MAGE, and VP-MAGE221-249 are shown. After 24 h cells were placed in medium containing 1 M MG132, a proteosome inhibitor
which was readded in fresh medium the next day, and cells were harvested 1 h later. Protein extracts in IB lysis buffer (60 g protein/lane) were
separated on a 12% acrylamide gel containing SDS. Transfer blots were probed with GAL-4 (left two lanes) and VP16 antibodies (right two lanes).
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(Fig. 4A) within the 	-helical region between amino acids 221
and 249 predicted by PONDR plot (http://www.pondr.com)
prompted us to test MAGE221-249 for its ability to interact
with AR. We found that Flag-MAGE221-249 did not stabi-
lize AR in cell extracts in the absence of DHT (Fig. 4D, lower
panel). Moreover, coimmunoprecipitation of AR with Flag-
MAGE221-249 decreased relative to full-length Flag-MAGE
in the absence and presence of EGF (Fig. 4D, upper panel),
and MAGE221-249 did not increase AR transcriptional ac-
tivity (Fig. 4C). Loss of the AR coregulatory function of
MAGE-11 by MAGE221-249 appears to result from its in-
ability to bind the AR FXXLF motif. Two-hybrid interaction
assays using VP16 and GAL-4 fusion proteins demonstrated
that MAGE221-249 did not interact with the AR NH2-ter-
minal FXXLF motif-containing fragments AR1-660 and
AR16-36 (Fig. 4E, upper panel) under conditions where
MAGE221-249 mutant expression levels were similar to the
wild type (Fig. 4E, lower panel).
The results raised the possibility that EGF-dependent
ubiquitinylation sites among the lysine residues in the amino
acid 221 to 249 region are required for MAGE-11 to interact
with AR. The data suggested in addition that when MAGE-11 is
not bound to AR, the MAGE-11 NH2-terminal region has an
inhibitory effect on EGF-dependent ubiquitinylation of MAGE-11.
Identification and functional effects of site-specific ubiquiti-
nylation in MAGE-11. To identify the ubiquitinylation sites in
MAGE-11, we prepared a series of lysine-to-alanine mutants
in full-length MAGE-11 and tested their ability to increase AR
transcriptional activity in the absence and presence of tran-
scriptional intermediary factor 2 (TIF2), an SRC/p160 coacti-
vator that increases AR transcriptional activity (22, 24).
MAGE-K225A and -K236A increased AR transcriptional ac-
tivity similar to wild-type MAGE-11 in the absence and pres-
ence of coexpressed TIF2 (Fig. 5A). In contrast, MAGE-
K240A, -K245A, and the double and multiple lysine mutants
lost most of the stimulatory effect of MAGE-11 on AR tran-
scriptional activity in the absence or presence of TIF2 but
expressed at levels similar to the wild type (Fig. 5A, lower
panel).
The requirements for MAGE-11 ubiquitinylation in modu-
lating AR transcriptional activity were further evaluated by
testing the effects of the lysine mutants on AR AF2 activity in
the carboxyl-terminal region and AF1 activity in the NH2-
terminal region. To measure AF2 transcriptional activity, we
coexpressed TIF2 with AR120–472, an AR deletion mutant
that lacks the NH2-terminal AF1 region but retains the NH2-
terminal FXXLF motif region required for the AR N/C inter-
action and for MAGE-11 to interact with AR. We found that
the transcriptional activity of AR120–472 depends on the
coexpression of MAGE-11 and TIF2 (Fig. 5B). This reflects
the ability of MAGE-11 to bind the AR FXXLF motif and
relieve inhibition of AF2 recruitment of SRC/p160 coactivators
caused by the AR N/C interaction (1, 3, 21). MAGE-K240A
and -K245A did not activate AR120–472 in the presence of
coexpressed TIF2, whereas MAGE-K225A and -K236A re-
tained the activity of wild-type MAGE-11.
We found that the MAGE-11-dependent increase in AR
AF1 activity also depended on MAGE-11 residues Lys-240 and
Lys-245. The constitutive activity of AR1-660, an AR NH2-
terminal and DNA binding domain fragment assayed in the
absence of TIF2, increased with the coexpression of MAGE-11
(Fig. 5C). However, MAGE-K240A and -K245A were less
effective than wild-type MAGE-11 and the K236A mutant in
increasing AR AF1 activity. The coregulatory function of
MAGE-11 was abolished by the triple mutation K236A,K240A,
K245A.
Two-hybrid interaction assays demonstrated that the inabil-
ities of MAGE-K240A and -K245A to increase AR transcrip-
tional activity resulted from ineffective binding of MAGE-11 to
the AR FXXLF motif. The GAL-4 and VP16 fusion proteins
of the MAGE-11 lysine-to-alanine mutants’ expression levels
were similar to the wild type but lost to varying degrees the
ability to interact with the AR FXXLF motif-containing frag-
ments VP-AR1-660 and GAL-AR16-36 (Fig. 5D). MAGE-
K240A, MAGE-K245A, and the multiple site mutants showed
the greatest loss of binding to AR, providing further evidence
that Lys-240 and Lys-245, and possibly Lys-236, are required
for MAGE-11 to interact with AR and increase AR transcrip-
tional activity.
The results suggest that EGF-dependent ubiquitinylation of
MAGE-11 at Lys-240 and Lys-245 is required for MAGE-11 to
increase AR transcriptional activity.
Dependence of the AR-MAGE interaction on ubiquitinyla-
tion. To establish whether the EGF-dependent ubiquitinyla-
tion of MAGE-11 occurs at the same lysine residues required
for MAGE-11 to bind AR, we tested the effect of the lysine
mutations on the EGF-dependent stabilization of the AR-
MAGE complex and the appearance of the slower migrating
forms of MAGE-11. We found that AR levels were lower in
the presence of MAGE-K240A compared to wild-type
MAGE-11 in extracts from cells treated in the absence or
presence of EGF (Fig. 6A, third panel, lanes 13 to 16). More-
over, coimmunoprecipitation of MAGE-11 and AR was dimin-
ished by the K240A mutation (Fig. 6A, upper panel, lanes 13
to 16) to a similar extent as the K245A (data not shown)
and K225A,K236A,K240A,K245A mutations (Fig. 6A, upper
panel, lanes 9 to 12). EGF-dependent immunoprecipitation of
the slower migrating forms of MAGE-112-429 and the -K236A
mutant was almost eliminated by the single K240A and K245A
or multiple K236A,K240A,K245A mutations (Fig. 6B, lower
panel), even though expression levels were similar (Fig. 6B,
upper panel).
Multiple ubiquitinylated forms of MAGE-11 could result
from polyubiquitinylation of MAGE-bound ubiquitin or mul-
tiple monoubiquitinylation of MAGE-11. To test this, we per-
formed experiments using lysine-free Flag-Ub-KO, in which all
ubiquitin lysine residues were mutated to arginine in order to
prevent polyubiquitinylation of MAGE-bound ubiquitin. We
found that ubiquitinylated forms of MAGE-11 persisted when
we used lysine-free ubiquitin, although there was a change in
the migration pattern (Fig. 6C, lanes 3 to 6), suggesting both
mono- and polyubiquitinylation of MAGE-11. However, we
found that AR coimmunoprecipitated to a similar extent as
wild type and lysine-free Flag-Ub in a DHT- and EGF-depen-
dent manner that required the presence of MAGE-11 (Fig. 6C,
lanes 7 to 18). Coimmunoprecipitation of AR with Flag-Ub in
the presence of HA-MAGE-112-429 (Fig. 6D, lanes 3 to 12)
did not occur in the presence of HA-MAGE-112-429-
K236A,K240A,K245A (Fig. 6D, lanes 13 to 16, 3KA).
The results suggest that EGF enhances mono- and poly-
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ubiquitinylation of MAGE-11 at sites that include lysine resi-
dues 240 and 245 and that multiple monoubiquitinylation of
MAGE-11 is required for the formation of the AR-MAGE
complex. Absence of AR in the coimmunoprecipitates without
the coexpression of MAGE-11 (Fig. 6C, lanes 7 to 10, and D,
lanes 3 to 6) indicated that AR was not ubiquitinylated under
the assay conditions.
Phosphorylation of MAGE-11. EGF signaling influences
transcriptional events through protein phosphorylation. We
therefore sought to identify the phosphorylation sites in
MAGE-11 that influence EGF-dependent ubiquitinylation of
MAGE-11 and its ability to increase AR transcriptional activ-
ity. Gel migration profiles were compared between wild-type
HA-MAGE-112-362 and with single and multiple serine-to-
FIG. 5. Inhibition of MAGE-11 coregulator function by lysine mutations. (A) Decreased AR transcriptional activity by MAGE-11 lysine
mutants. CV1 cells were transfected with 5 g PSA-Enh-Luc and 0.1 g pCMV-AR in the absence and presence of 2 g pSG5-TIF2 and 2 g
pSG5-MAGE wild-type (WT) and the indicated lysine-to-alanine mutants. Cells were incubated for 48 h in the absence and presence of 1 nM
DHT, and luciferase activity was measured. The lower panel shows immunoblot results with cell extracts from COS cells transfected with 4 g pSG5
empty vector (
), wild-type (WT) pSG5-MAGE, or the indicated lysine-to-alanine mutants. Protein extracts (20 g/lane) were separated on a 10%
gel, and the transfer blot was probed with MagAb13-26 antibody. (B) Inability of MAGE-K240A and MAGE-K245A to increase AR AF2 activity.
CV1 cells were transfected with 5 g MMTV-Luc, 0.1 g pCMV-AR120–472 (with a deletion of the AR NH2-terminal AF1 region) with 2 g
WT pSG5-MAGE alone, 2 g pSG5-TIF2 alone, and 2 g pSG5-TIF2 with 2 g WT pSG5-MAGE and K225A, K236A, K240A and K245A
mutants as indicated. Cells were incubated for 48 h in the absence and presence of 1 nM DHT, and luciferase activity was measured. (C) Effects
of MAGE-11 lysine mutants on AR AF1 constitutive activity. HeLa cells were transfected with 0.1 g PSA-Enh-Luc and 0.01 g pCMV-AR1-660
in the absence and presence of 0.1 g WT pSG5-MAGE and K236A, K240A, K245A, and K236A,K240A,K245A mutants as indicated. Cells were
incubated for 48 h before measuring luciferase activity. (D) Two-hybrid interaction between AR and MAGE-11 lysine mutants. HeLa cells were
transfected with 0.25 g 5XGAL4Luc3 and 0.05 g WT or the indicated lysine-to-alanine mutant in GAL-MAGE or VP-MAGE with 0.05 g
VP-AR1-660 or GAL-AR16-36. The next day cells were incubated for 48 h before measuring luciferase activity. (Inset) immunoblots of extracts
from COS cells transfected with 8 g GAL-0 (
) and WT and mutant GAL-MAGE (top panel) and pVP16 (
) and WT and mutant VP-MAGE
(bottom panel), as indicated. After 24 h, cells were transferred to medium containing 1 M MG132, which was readded in fresh medium the next
day and cells were harvested 1 h later. Protein extracts in IB lysis buffer (50 g/lane) were separated on 10% acrylamide gels containing SDS.
Transfer blots were probed using GAL-4 (upper panel) and VP16 (lower panel) antibodies.
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alanine mutations at consensus phosphorylation sites. Extracts
from EGF-treated cells were analyzed with and without treat-
ment with -phosphatase.
We found that EGF increased, and -phosphatase slowed,
the electrophoretic mobility of MAGE-112-362 and its EGF-
induced ubiquitinylated forms (Fig. 7A, top panel, lanes 1 to 3,
and lower panel, lanes 16 and 17), suggesting the changes in gel
migration are indicative of phosphorylation. Phosphatase
treatment slowed the migration of MAGE-112-362 with indi-
vidual mutations at predicted consensus phosphorylation sites
Ser-174, Ser-181, and Ser-208 but had less of an effect on the
S174A,S181A,S208A triple mutant (Fig. 7A, upper panel). In
contrast, migration of MAGE-112-362 with simultaneous mu-
tations at Ser-168, -170, -174, -181, -199, and -208 was unal-
tered by EGF with or without phosphatase treatment (Fig. 7A,
lower panel, lanes 23 to 25).
The results suggest that EGF-dependent phosphorylation of
MAGE-11 occurs among serine residues 168, 170, 174, 181,
199, and 208. Phosphorylation at Ser-208 was confirmed by
mass spectrometry (data not shown). However, none of these
single or multiple serine mutations diminished the ability of
full-length MAGE-11 to increase AR transcriptional activity,
as shown for the six-serine mutant (Fig. 7B, 6-SA). In addition,
the greater intensity of the slower migrating ubiquitinylated
forms of the serine-to-alanine MAGE-11 mutants observed
after treatment with EGF (Fig. 7A) indicated that serine phos-
phorylation among these sites does not influence the EGF-
dependent ubiquitinylation of MAGE-11.
FIG. 6. Requirement of MAGE-11 ubiquitinylation to interact with AR. (A) COS cells were transfected with 1 g pCMV-AR in the presence
of 4 g Flagb empty vector (lanes 1 to 4), wild-type (WT) Flag-MAGE (lanes 5 to 8), Flag-MAGE-K225A,K236A,K240A,K245A (lanes 9 to 12),
or Flag-MAGE-K240A (lanes 13 to 16). Cells were treated 24 h later in the absence and presence of 10 nM DHT and 100 ng/ml EGF as indicated.
The next day media were replaced and cells were incubated for 2 h at 37°C. Flag-MAGE was immunoprecipitated using anti-Flag M2 affinity resin,
and the immunoprecipitates (upper two panels) and cell extracts (10 g/lane; lower two panels) were separated on 10% acrylamide gels. Transfer
blots were probed using AR32 and anti-Flag M2 monoclonal antibodies. (B) COS cells were transfected with 6 g Flagb (lanes 1, 4, 7, 10, and 13)
(
) and 6 g FlagUb as indicated with 2 g WT pSG5-HA-MAGE-112-429 and the indicated lysine-to-alanine mutants. After 24 h cells were
treated in the absence and presence of 100 ng/ml EGF as indicated. Cells were harvested the next day, and protein extracts were immunopre-
cipitated using anti-Flag M2 affinity resin. Immunoprecipitates were separated on 10% acrylamide gels containing SDS. Transfer blots were probed
for MAGE-11 using HA tag antibody. X-ray film was exposed for 5 s (upper panel) and 20 min (lower panel). (C) In the left panel, COS cells were
transfected with 3 g pSG5-HA-MAGE-112-429 together with 6 g Flagb (lanes 1 and 2), 6 g Flag-Ub (lanes 3 and 4), and 6 g Flag-Ub-KO,
in which all ubiquitin lysine residues were changed to arginine (lanes 5 and 6). In the right panels, COS cells were transfected with 2 g pCMV-AR
together with 6 g Flagb (lanes 7 to 10), 6 g Flag-Ub and 3 g pSG5-HA-MAGE-112-429 (lanes 11 to 14), and 6 g Flag-Ub-KO and 3 g
pSG5-HA-MAGE-112-429 (lanes 15 to 18). Cells were incubated for 24 h in the absence and presence of 10 nM DHT and 10 ng/ml EGF as
indicated, and extracts were prepared in IB (lanes 1 to 6) and IP (lanes 7 to 18) lysis buffer and analyzed by immunoblotting with AR32 and HA
tag antibodies. (D) COS cells were transfected with 6 g Flagb and 3 g pSG5-HA-MAGE-112-429 (lane 1), 6 g Flagb and 3 g pSG5-HA-
MAGE-112-429-K236A,K240A,K245A (HA-MAGE-112-3KA, lane 2), 6 g Flag-Ub and 2 g pCMV-AR (lanes 3 to 6), 6 g Flag-Ub and 3 g
pSG5-HA-MAGE-112-429 in the absence (lanes 7 and 8) and presence (lanes 9 to 12) of 2 g pCMV-AR, and 6 g Flag-Ub with 3 g pSG5-
HA-MAGE-112-429-K236A,K240A,K245A (HA-MAGE-112-3KA) in the presence (lanes 13 to 16) and absence (lanes 17 and 18) of 2 g
pCMV-AR. Cells were incubated for 24 h in the absence and presence of 10 nM DHT and 100 ng/ml EGF as indicated and extracted in IP lysis
buffer. The blots were probed with AR32, HA, and -actin antibodies as indicated.
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FIG. 7. Phosphorylation sites in MAGE-11. (A) Effects of -phosphatase on the electrophoretic mobility of MAGE-11 serine mutants. COS
cells were transfected with 2 g wild-type (WT) pSG5-HA-MAGE-112-362 and with the indicated serine-to-alanine mutants. The next day cells
were incubated for 24 h in the absence and presence of 100 ng/ml EGF as indicated. Media with and without EGF were replaced and cells were
incubated an additional 2 h at 37°C and harvested in 0.2 ml IP lysis buffer without sodium fluoride. Protein extracts (2 g) from EGF-treated cells
were incubated in 40 l for 1 h at 4°C with and without 400 IU -phosphatase (New England Biolabs). Samples were analyzed on 12% acrylamide
gels containing SDS, and transfer blots were probed with HA tag antibody. Shown are the major (arrow) and slower-migrating ubiquitinylated
forms of WT and mutant HA-MAGE-112-362. (B) MAGE-T360A lacks coactivator activity. CV1 cells were transfected with 5 g PSA-Enh-Luc
and 0.1 g pCMV-hAR with and without 1 g WT pSG5-MAGE and the S168A,S170A,S174A,S181A,S199A,S208A (6-SA) and T360A mutants
as indicated. Cells were incubated in the absence and presence of 1 nM DHT for 48 h, and luciferase activity was determined. In the lower panel,
expression levels of WT and mutant pSG5-MAGE were determined by transfecting COS cells with 4 g pSG5 empty vector (lane 1), WT
pSG5-MAGE (lane 2), and the 6-SA (lane 3) and T360A (lane 4) mutants. Protein extracts (2 g/lane) were analyzed by immunoblotting using
MagAb59-79 antibody. (C) Lack of AR AF2 transcriptional response to MAGE-T360A. CV1 cells were transfected with 5 g MMTV-Luc and
0.1 g pCMV-AR120–472 in the absence and presence of 2 g pSG5-TIF2 and 2 g WT pSG5-MAGE, 6-SA, and T360A mutant as indicated.
Cells were incubated in the absence and presence of 1 nM DHT for 48 h, and luciferase activity was measured. (D) Lack of AR AF1 transcriptional
response to MAGE-T360A. HeLa cells were transfected with 0.1 g PSA-Enh-Luc with 0.01 g pCMV5 empty vector (p5) and 0.01 g
pCMV-AR1-660 in the absence and presence of 0.1 g WT pSG5-MAGE, 6-SA, or T360A mutants as indicated. Luciferase activity was measured
48 h later. (E) Phosphorylation at MAGE-11 Thr-360. COS cells were transfected with 5 g WT pSG5-HA-MAGE-112-429 and the T360A mutant
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We extended our studies on MAGE-11 phosphorylation to
consensus threonine phosphorylation sites and found that
phosphorylation at Thr-360 is essential for MAGE-11 to in-
crease AR transcriptional activity. In contrast to wild-type
MAGE-11 and the 6-SA mutant, MAGE-T360A did not in-
crease the transcriptional activity of AR120–472 assayed in
the presence of TIF2 (Fig. 7C) or the constitutive activity of
AR1-660 (Fig. 7D). MAGE-T360A activity was expressed at a
similar level as wild-type MAGE-11 and the 6-SA mutant, and
MAGE-6SA, but not MAGE-T360A, migrated slightly slower
than wild-type MAGE-11 (Fig. 7B, lower panel), in agreement
with the results in Fig. 7A.
In support of MAGE-11 Thr-360 phosphorylation, we found
a 2-fold increase in immunoreactivity of HA-MAGE-112-429
in response to EGF using a phosphothreonine antibody based
on the ratio of phosphothreonine to HA antibody reactivity
and incubated for 24 h in the absence and presence of 100 ng/ml EGF and again in fresh medium for 2 h. Cells were extracted in IP lysis buffer,
and equivalent amounts of protein were immunoprecipitated using an anti-HA affinity matrix (15 l/470 g protein). Immunoprecipitates were
analyzed using HA tag antibody (1/10 of immunoprecipitate) and antiphosphothreonine antibody (9/10 of immunoprecipitate). Immunoblots were
quantitated using an Image-Pro Plus spectrophotometer to obtain the ratio of phosphothreonine antibody to HA antibody reactivity. (F) Chk1
kinase phosphorylation of MAGE-11 Thr-360. An in vitro kinase assay was performed using GST-Chk1 kinase together with GST-210GLYRSP
SMPE219, which is a GST-Cdc25C truncated fusion peptide substrate for Chk1 kinase (BioVision Inc.) (lane 1), GST-0 empty vector (lane 2), WT
GST-MAGE-354EPKRLLTQN362 (lane 3), and GST-MAGE-354EPKRLLAQN362 T360A mutant (lane 4) (upper panel). Reactions were
performed as described in Materials and Methods at 30°C for 30 min. The 30-kDa band is phosphorylated WT GST-MAGE-354-362, and the
82-kDa band appears to be autophosphorylated GST-Chk1 kinase. The rehydrated stained gel indicated equivalent protein loading (lower
panel).
FIG. 8. Functional requirement of MAGE-11 Thr-360. (A) Reduced AR interaction with MAGE-T360A. COS cells were transfected with 2
g pCMV-AR together with 4 g Flagb empty vector (lanes 1 to 4), Flag-MAGE (lanes 5 to 9), or Flag-MAGE-T360A (lanes 9 to 12). The next
day cells were treated for 24 h and again for 2.5 h in the absence and presence of 10 nM DHT and 100 ng/ml EGF as indicated. Transfer blots
containing the immunoprecipitates (top panel) and cell extracts (15 g protein/lane) (bottom panel) were probed with anti-Flag M2 monoclonal,
AR32, and -actin antibodies. (B) Reduced ubiquitinylation of MAGE-T360A. COS cells were transfected with 6 g Flagb (
) and FlagUb as
indicated with 3 g wild-type (WT) pSG5-HA-MAGE-112-429 (lanes 1 to 3), and the T360A (lanes 4 to 6), K236A,K240A,K245A (lanes 7 to 9),
and S168A,S170A,S174A,S181A,S199A,S208A (6-SA; lanes 10 to 12) mutants. Cells were incubated the next day in the absence and presence of
100 ng/ml EGF and 24 h later harvested for immunoprecipitation using anti-Flag affinity resin. The blot was probed using HA tag antibody.
(C) Two-hybrid assay showing loss of MAGE-T360A interaction with AR. HeLa cells were transfected with 0.1 g 5XGAL4Luc3 and 0.05 g WT
GAL-MAGE, the T360A and K240A,K245A mutants, and pVP16 empty vector or VP-AR1-660 (VP-AR) as indicated, and with 0.05 g WT
VP-MAGE and the T360A and K240A,K245A mutants with 0.05 g GAL-0 empty vector or GAL-AR16-36 (GAL-AR) as indicated. Luciferase
activity was determined 48 h later. The lower panel shows protein extracts that were analyzed by immunoblotting from COS cells transfected with
8 g GAL-0 empty vector, WT GAL-MAGE, and the T360A and K240A,K245A mutants (50 g protein/lane) and pVP16 empty vector, WT
VP-MAGE, and the T360A and K240A,K245A mutants (60 g protein/lane) as indicated. Transfer blots were probed using GAL-4 (left panel)
and VP16 (right panel) antibodies.
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(Fig. 7E, lanes 2 and 3). Phosphothreonine antibody immuno-
reactivity by the HA-MAGE-112-429-T360A mutant was two-
to fourfold less than wild type and was not altered by EGF
(Fig. 7E, lanes 2 to 5). Based on a predicted cell cycle check-
point Chk1 kinase phosphorylation site at MAGE-11 Thr-360,
we also performed an in vitro kinase assay using a GST-Cdc25
Chk1 substrate fusion peptide as a control (Fig. 7F, lane 1) and
GST-MAGE-354-362 and the corresponding T360A mutant.
The MAGE-11 peptide was phosphorylated by Chk1 kinase in
a site-specific manner that was eliminated by the T360A mu-
tation (Fig. 7F, lanes 3 and 4).
In studies to test the effect of the T360A mutation on the
AR-MAGE interaction, we found that coimmunoprecipitation
of AR with Flag-MAGE-T360A was reduced in the presence
of EGF and absence of DHT (Fig. 8A, lanes 7 and 11). How-
ever, AR remained detectable at a reduced level in the coim-
munoprecipitates with Flag-MAGE-T360A in the presence of
EGF alone or with EGF and DHT (Fig. 8A, upper panel),
similar to that seen for MAGE221–249 (Fig. 4D) and the
ubiquitinylation site mutants (Fig. 6A) that lose AR coactiva-
tor function (Fig. 4C and 5A to C). The T360A mutation
reduced the ubiquitinylation of MAGE-11 in the presence of
EGF to an extent similar to MAGE-K236A,K240A,K245A
(Fig. 8B). In two-hybrid assays, MAGE-T360A did not in-
teract with the AR NH2-terminal FXXLF motif-containing
fragments VP-AR1-660 and GAL-AR16-36 (Fig. 8C, upper
panel), even though the wild-type and mutant GAL- and
VP-MAGE fusion proteins were expressed at similar levels
(Fig. 8C, lower panels).
The results suggest that EGF increases AR transcriptional
activity through the phosphorylation of MAGE-11 Thr-360,
which targets MAGE-11 for ubiquitinylation.
Effects of MAGE-11 on AR transcriptional activity in Ish-
ikawa cells. To further establish a link between the effects of
EGF on the MAGE-11-dependent increase in AR transcrip-
tional activity, we directed our studies to the human endome-
trial Ishikawa cell line. Ishikawa cells express AR and MAGE-
11, but at low levels that require transient expression of AR to
activate a reporter gene (2). Initially we tested the EGF de-
pendence of AR transcriptional activity in Ishikawa cells and
the functional effects of the phosphorylation and ubiquitinyla-
tion site mutants that eliminate the coactivator function of
MAGE-11. We found that DHT increases AR transcriptional
activity in Ishikawa cells to a greater extent in the presence of
EGF (Fig. 9A). Furthermore, AR activity was enhanced by
FIG. 9. Effects of MAGE-11 on AR transcriptional activity in Ish-
ikawa cells. (A) Ishikawa cells (105/well in 12-well plates) were trans-
fected using FuGENE-6 with 0.1 g PSA-Enh-Luc, 0.01 g pCMV-
AR, and 0.1 g pSG5, wild-type pSG5-MAGE, or the S168A,S170A,
S174A,S181A,S199A,S208A (6-SA), T360A, and K236A,K240A,
K245A mutants as indicated. Cells were incubated in the absence and
presence of 1 nM DHT and 100 ng/ml EGF for 24 h as indicated, and
luciferase activity was measured. (B) Time dependence of the EGF-
induced increase in AR1-660 activity. Ishikawa cells (7.5  104/well)
were plated (day 1) in separate 12-well plates according to the time of
harvest and transfected (day 2) with 0.1 g MMTV-Luc and 0.05 g
pCMV5 (p5) and 0.05 g pCMV-AR1-660 as indicated using
FuGENE-6. On day 3, cells were cultured in the absence and presence
of 10 ng/ml EGF. The next day (day 4), the media were exchanged and
cells were harvested for luciferase activity (day 3, 24 h) or further
incubated for the indicated times in the absence and presence of 10
ng/ml EGF. Cells were solubilized in luciferase lysis buffer and lysates
were stored at 
20°C until analysis for luciferase activity, which was
stable to freeze-thaw. (C) Inhibition of AR transcriptional activity by
MAGE-11 siRNA. Ishikawa cells (105/well in 12-well plates) were
transfected using Lipofectamine 2000 with 0.1 g MMTV-Luc and
0.025 g pCMV-AR in the absence and presence of 2 nM MAGE-11
siRNA-2 and siRNA-3 as indicated. Twenty-four h after transfection,
cells were placed in serum-free, phenol red-free medium without hor-
mone treatment. After 24 h the medium was replaced with fresh
medium with and without 0.1 nM DHT and 10 ng/ml EGF as indicated.
Cells were cultured another 24 h, and luciferase activity was mea-
sured. (Inset) Inhibition of MAGE-11 expression by siRNA. COS
cells (4  105/well in six-well plates) were transfected using Lipo-
fectamine 2000 in Dulbecco’s modified Eagle’s medium without
antibiotics with 0.5 g pSG5 (p5, lane 1) and 0.5 g pSG5-MAGE
in the absence (lane 2) and presence of 10 nM MAGE-11 siRNA-1
(lane 3), siRNA-2 (lane 4), and siRNA3 (lane 5). Cells were ex-
tracted in IB lysis buffer and analyzed (10 g/lane) on immunoblots
using MagAb13-26 and -actin antibodies.
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coexpressing wild-type MAGE-11 or the 6-SA mutant in the
absence and presence of EGF. However, in agreement with the
results presented above, the coactivator function of MAGE-11
was abolished by the T360A and K236A,K240A,K245A muta-
tions. The results indicate that in Ishikawa cells, the AR coac-
tivator function of MAGE-11 requires the same MAGE-11
threonine phosphorylation and lysine ubiquitinylation sites.
To relate the time-dependent EGF-induced stabilization of
the MAGE-AR-DHT complex (Fig. 1B) to the EGF-depen-
dent increase in AR transcriptional activity in Ishikawa cells
(Fig. 9A), we expressed AR1-660, the constitutively active AR
NH2-terminal and DNA binding domain fragment, without
coexpressing MAGE-11. AR1-660 transcriptional activity was
increased after 24 and 48 h in response to EGF, but the
increase was detected only after 9 to 14 h of exposure of cells
to EGF (Fig. 9B). Maximal EGF induction of AR1-660 tran-
scriptional activity occurred between 24 and 48 h, whereas
AR1-660 transcriptional activity was constant over the 48 h of
culture in the absence of EGF.
The remarkably similar 10-h time dependence of the EGF-
induced increase in AR transcriptional activity (Fig. 9B) and
EGF-dependent stabilization of the MAGE-AR-DHT com-
plex (Fig. 1B) supported the possibility that EGF increased AR
activity in Ishikawa cells through endogenous MAGE-11. To
address this, we cotransfected Ishikawa cells with siRNA-2,
which reduces MAGE-11 expression, and siRNA-3, which
does not (Fig. 9C, inset). We found that siRNA-2, but not
siRNA-3, reduced full-length AR transcriptional activity in the
absence and presence of EGF (Fig. 9C), suggesting that the
DHT- and EGF-dependent increase in AR transcriptional ac-
tivity in Ishikawa cells involves endogenous MAGE-11.
DISCUSSION
Modulation of AR transcriptional activity by the N/C inter-
action and MAGE-11. AR transcriptional activity relies on a
complex sequence of events involving a potentially large num-
ber of coregulatory proteins through mechanisms that are not
well understood (29). One regulatory mechanism that modu-
lates AR transcriptional activity is the androgen-dependent
AR N/C interaction between the NH2-terminal FXXLF motif
and AF2 in the ligand binding domain (21, 26, 30, 40, 51, 57).
The AR N/C interaction depends on high-affinity binding of
testosterone, DHT, or synthetic anabolic steroids, which are
agonists in vivo (36, 62). The functional importance of the AR
N/C interaction in androgen-dependent gene regulation is sup-
ported by naturally occurring AR AF2 site mutations that
cause the androgen insensitivity syndrome, reduce AR FXXLF
motif binding, and increase the dissociation rate of bound
androgen without altering the apparent equilibrium androgen
binding affinity (15, 22, 34, 49, 57).
However, these same AF2 site mutations that disrupt AR
FXXLF motif binding also inhibit AR AF2 recruitment of
SRC/p160 coactivator LXXLL motifs, which bind with at least
5- to 10-fold-lower affinity than the FXXLF motifs present in
AR (22, 23), putative AR coregulators (27, 32, 58), and pep-
tides identified in peptide display screens (8, 14, 31). Crystal
structures of the AR ligand binding domain bound to natural
or synthetic androgen agonists have demonstrated overlapping
AF2 binding sites for the FXXLF and LXXLL motifs (1, 22,
23, 32), supporting their physiological relevance in AR func-
tion. Coexpression of SRC/p160 coactivators can increase AR
transcriptional activity in an LXXLL motif-dependent manner
(26), even though the AR FXXLF motif binding to AF2 has an
inhibitory effect on the recruitment of SRC/p160 coactivator
LXXLL motifs (21). Weaker coactivator LXXLL motif bind-
ing to AR may be compensated by higher cell and tissue-
specific expression levels of the SRC/p160 coactivators, as re-
ported in prostate cancer (17). The higher-affinity AR FXXLF
motif binding supports the biological importance of the AR
N/C interaction and suggests a regulatory function in modu-
lating the transcriptional effects of SRC/160 coactivators.
The apparent dual function of the AR AF2 site in establish-
ing AR transcriptional activity is controlled in part by MAGE-
11, an AR coregulator that selectively binds the FXXLF motif
region of AR and competes for the AR N/C interaction.
MAGE-11 increases overall AR transcriptional activity by ex-
posing AF2 to coactivator recruitment (3) and through addi-
tional mechanisms independent of AF2. The MAGE-11-in-
duced increase in AR transcriptional activity at enhancer
elements that require the AR N/C interaction for maximal
activity (3, 26) suggests a complex interrelationship between
AR AF2 transcriptional activity and MAGE-11 binding that is
modulated by interactions at the AR FXXLF motif.
EGF regulation of AR through MAGE-11. In this report we
provide evidence that EGF cell signaling increases AR tran-
scriptional activity through the posttranslational modification
of MAGE-11. We demonstrated that EGF induces the ubiq-
uitinylation of MAGE-11 at Lys-240 and Lys-245, two residues
that are also required for MAGE-11 to interact with the AR
NH2-terminal FXXLF motif. Mutations at these residues re-
duce the EGF-dependent ubiquitinylation of MAGE-11 and
cause MAGE-11 to lose coregulator function. In the absence
of DHT and EGF, interaction of the transcriptionally inactive
AR with MAGE-11 through the AR FXXLF motif depends on
the ubiquitinylation of MAGE-11. AR is also detected in as-
sociation with MAGE-11 at reduced levels independent of the
lysine ubiquitinylation sites, raising the possibility of a second
weaker interaction site not directly linked to coactivator func-
tion. Stable complex formation between AR and MAGE-11 in
the absence of androgen is unimpeded by the androgen-de-
pendent AR N/C interaction and increases AR levels, provid-
ing a mechanism for greater AR transcriptional activity in
response to low levels of androgen.
In the presence of DHT, the androgen-dependent AR N/C
interaction of the transcriptionally active AR competes with
AR FXXLF motif binding to MAGE-11. Just as MAGE-11
stabilizes AR in the absence of androgen, AR is stabilized in
the presence of androgen by the AR N/C interaction, providing
a second mechanism to increase overall cell content of AR for
gene activation. The transient nature of the MAGE-AR-DHT
complex in the presence of DHT without EGF signaling ap-
pears to reflect this competitive relationship that is centered on
the AR FXXLF motif. However, in the presence of DHT and
EGF, AR transcriptional activity increases, dependent on in-
creased ubiquitinylation of MAGE-11 and stabilization of the
MAGE-AR-DHT complex.
The somewhat paradoxical effects of EGF to increase AR
transcriptional activity through the stabilization of the MAGE-
AR-DHT complex yet to increase MAGE-11 turnover may
VOL. 28, 2008 EGF UBIQUITINYLATION OF AR COREGULATOR MAGE-11 1959
FIG. 10. Sequence alignment of the MAGE superfamily. Amino acid sequence alignment was performed using PredictProtein (http://www
.predictprotein.org) and is shown for MAGE-11 of the MAGE-A subfamily, the first four members of the MAGE-A subfamily, and the primary
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reflect the EGF-dependent increase in the mono- and poly-
ubiquitinylation of MAGE-11. We provide evidence that
monoubiquitinylation of MAGE-11 is required for the AR-
MAGE interaction and coregulator function of MAGE-11.
Increased MAGE-11 degradation in response to EGF may
occur in response to polyubiquitinylation of MAGE-bound
ubiquitin. The apparent inhibitory effect of the MAGE-11
NH2-terminal region on ubiquitinylation in the absence of AR
suggests that binding to AR may increase exposure of the
MAGE-11 ubiquitinylation sites, leading to increased MAGE-11
turnover and greater AR transcriptional activity.
EGF-dependent stabilization of the MAGE-AR-DHT com-
plex requires 10 h in cell culture, a time period that was also
required for EGF to increase AR transcriptional activity in
Ishikawa cells that express endogenous MAGE-11. It is there-
fore tempting to speculate that the effects of EGF on
MAGE-11 are linked to progression through the cell cycle.
This hypothesis gained support by evidence that MAGE-11 is
phosphorylated at Thr-360 by the cell cycle checkpoint kinase
Chk1. The inability of the MAGE-T360A mutant to interact
with AR and increase AR transcriptional activity suggests that
phosphorylation at Thr-360 by Chk1 kinase is part of a mech-
anism whereby EGF triggers the ubiquitinylation of MAGE-11
in association with increased AR transcriptional activity. The
inability of a phosphorylation mimetic (MAGE-T360E) to res-
cue the interaction with AR in two-hybrid assays (data not
shown) may reflect the transient nature of Thr-360 phosphor-
ylation or the different carbon atom positions of the glutamic
acid carboxyl group and threonine phosphate group. We also
presented evidence for multiple serine phosphorylation sites
in MAGE-11, even though none of the serine mutations
diminished the ability of MAGE-11 to increase AR tran-
scriptional or influenced the EGF-dependent ubiquitinyla-
tion of MAGE-11 and its interaction with AR. Threonine
residues are estimated to be nine times less likely than
serine to be sites of phosphorylation and more often serve in
a signaling capacity (46).
Our results are consistent with the hypothesis that EGF
increases the multiple monoubiquitinylation of MAGE-11 in
association with time-dependent stabilization of the MAGE-
AR-DHT complex and increased degradation of MAGE-11.
EGF increases the phosphorylation and ubiquitinylation of
MAGE-11, which enhances its interaction with DHT-bound
AR. At the same time, EGF-dependent phosphorylation of
MAGE-11 is linked to increased polyubiquitinylation and ac-
celerated turnover of MAGE-11. While the precise sequence
of events remains to be determined, EGF-dependent phosphor-
ylation and ubiquitinylation of MAGE-11 appears to be part of
a processive cycle that allows AR to release and reassociate
with coactivators and the transcription complex through mul-
tiple rounds of gene activation. The effect of EGF to stabilize
the DHT-bound AR interaction with MAGE-11 provides a
mechanism to prolong AR-driven gene transcription.
EGF signaling and AR transcriptional activity. EGF signal-
ing has been linked to increased AR transcriptional activity
through ligand-dependent and -independent mechanisms in
prostate cancer by increased coactivator recruitment (12, 13,
16, 18, 44). More recently, ubiquitin-proteasome pathways
have gained attention for their role in chromatin remodeling
by nuclear receptors (37) and in the phosphorylation and ubiq-
uitinylation of RNA polymerase (4, 47). However, to our
knowledge, growth factor signaling has not been linked to
steroid hormone receptor regulation through the site-specific
ubiquitinylation of a coregulator. Ubiquitinylation of coactiva-
tor proteins such as SRC3/AIB1 was shown to be modulated by
phosphorylation and may occur in a processive manner in
association with gene activation (41, 61). A similar mechanism
likely occurs in AR-directed gene transcription and involves
the AR N/C interaction and binding of MAGE-11.
Although we found no evidence that AR itself was ubiquiti-
nylated in the present study, AR undergoes rapid degradation
in the absence of androgen or MAGE-11 (35) and is reportedly
linked to a proteosome-mediated mechanism (52) through a
direct interaction between AR and the E3 ubiquitin ligase
Hsp70/Hsp90 cochaperone, the carboxyl terminus of Hsp70
interacting protein (CHIP). CHIP interacts with AR through a
highly conserved AR NH2-terminal domain sequence (20). A
regulatory role for CHIP in AR function is supported by the
spontaneous AR somatic missense mutation AR-E231G in a
mouse model of prostate cancer, which inhibits CHIP binding
and may contribute to prostate neoplasia (19, 20). Whether
CHIP is involved in AR modulation by MAGE-11 in normal
human physiology or prostate cancer remains to be deter-
mined. AR transcriptional activity was also reported to be
increased by AR monoubiquitinylation through increased in-
teraction with coregulatory proteins (6) in association with the
phosphorylation and increased degradation of AR (42).
The AR selective coregulatory function of MAGE-11 is sup-
ported by the cell and tissue expression profiles. Both AR and
MAGE-11 are expressed in normal tissues of the human male
and female reproductive tracts and in prostate cancer cell lines
(2, 3). MAGE-11 is expressed in a temporal fashion in glan-
dular epithelial cell nuclei of normal cycling human endome-
trium and is hormonally regulated during the menstrual cycle
(2). MAGE-11 is down-regulated by estradiol during the pro-
liferative phase of the human endometrium and up-regulated
in response to cyclic AMP during the early and mid-secretory
stage. Highest levels of MAGE-11 mRNA and protein coin-
cide with the window of receptivity to embryo implantation,
suggesting a functional link between AR and MAGE-11 in
normal female fertility. Increased expression of MAGE-11
may also contribute to AR transcriptional activity in androgen-
member of MAGE subfamilies B to H. Amino acid residues are color coded for lysine and arginine (red), aspartic and glutamic acid (blue), glycine,
alanine, valine, leucine, isoleucine, proline, and methionine (green), cysteine (yellow), and Thr-360 (purple). Also indicated for MAGE-11 is the
nuclear localization signal (NLS, residues 18 to 23), the first and second (Met-111) methionine residues, the MAGE homology domain (MHD)
residues 222 to 421, Lys-240 and Lys-245 ubiquitinylation sites, and the Thr-360 phosphorylation site. Absence of sequence and minimal interior
spacing for optimal sequence alignment are designated by a dash. In two instances, lowercase letters signify deletion of an intervening proline.
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dependent and castration-recurrent prostate cancer, which typ-
ically expresses AR during androgen deprivation therapy when
circulating androgen levels are low.
Conservation of MAGE-11 phosphorylation and ubiquitiny-
lation sites throughout the MAGE gene family. MAGE-11
shares extensive sequence homology with the MAGE super-
family of so-called cancer-testis antigens (Fig. 10). MAGE-11
is a member of the MAGE-A subfamily that includes 12 pro-
teins coded at the Xq28 region of the human X chromosome
(10, 50, 54). Thus, both AR and MAGE-11 are expressed on
the human X chromosome (5). MAGE-11 is unique among the
MAGE family by having 89 NH2-terminal amino acid residues
encoded by three short 5 exons that include a nuclear target-
ing signal in the first coding exon (3, 33). All other MAGE-A
family members initiate at a methionine that corresponds to
Met-111 in MAGE-11 (shown for MAGE-A-1 to -4 in Fig. 10).
Within the carboxyl-terminal residue 112 to 429 region of
MAGE-11, which interacts with the AR FXXLF motif, is the
MAGE homology domain (MAGE-11 residues 222 to 421),
which is highly conserved throughout the entire MAGE gene
superfamily (Fig. 10). Our results therefore support the previ-
ous suggestion that the MAGE homology domain serves as a
protein-protein interaction site (56). It is also interesting that
the EGF-dependent Thr-360 phosphorylation site and Lys-240
and Lys-245 ubiquitinylation sites in MAGE-11 are among the
most highly conserved residues within the MAGE homology
domain throughout the MAGE superfamily (Fig. 10). This
raises the possibility that similar posttranslational modifica-
tions are involved in the as-yet-unknown functions of most of
the MAGE gene family. The apparent lack of a functional
homologue for MAGE-11 in rats and mice suggests a special-
ized function in human and nonhuman primate physiology to
increase and prolong AR transcriptional activity through
mechanisms downstream of growth factor signaling.
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